China's First Super-Microsurgery Robot 'Dishi Lingfeng' Successfully Completes First Patient Enrollment in Registered Clinical Trial for Lymphedema Treatment

September 2, 2026 — In a sterile operating room at Zhejiang Provincial People's Hospital, Professor Zheng Youmao sat at a console, his hands gliding over controls that translated every micro-movement into actions measured in microns. On the other side of the room, robotic arms held instruments finer than a human hair, stitching together lymphatic vessels no wider than a strand of spider silk.

By the time the procedure ended, the 56-year-old surgeon had done something no team in China had accomplished before: completed the first patient enrollment in a registered clinical trial using a surgical robot for lymphaticovenular anastomosis, or LVA — a procedure so delicate it has long been described as "dancing on the tip of a needle."

The robot that made it possible was the "Dishi Lingfeng," a domestically developed microsurgical system built by Hangzhou Dessight Biomedical Co. Ltd. Its successful deployment marks a milestone not just for the company, but for China's ambitions in high-end medical robotics — a field long dominated by Western manufacturers.

A Procedure at the Edge of Human Capability

Secondary lymphedema — the chronic, often disfiguring swelling that follows cancer surgery — affects hundreds of thousands of patients worldwide. After breast cancer operations, arms can balloon to twice their normal size. After gynecological tumor removal, legs become heavy, painful, prone to recurring infections. Traditional treatment relies on compression garments and manual drainage, managing symptoms but rarely addressing the root cause: blocked lymphatic channels with no way to reroute the flow.

LVA offers a surgical solution. Using microscopes and sutures thinner than a human hair, surgeons connect damaged lymphatic vessels to nearby veins, creating bypass routes that restore drainage. The results can be dramatic — reduced swelling, fewer infections, improved quality of life.

But the procedure has limits. The vessels available for anastomosis typically measure between 0.1 and 1 millimeter in diameter — approaching the physiological threshold of what human hands can reliably manipulate. Learning curves stretch over years. Hand tremors, fatigue, and the sheer tedium of working at that scale introduce variability that no surgeon, no matter how skilled, can entirely eliminate.

"The targets in super-microsurgery are generally smaller than 0.8 millimeters," Professor Zheng explained after the procedure. "The demands on hand-eye coordination and fine motor control are extreme."

Robots Enter the Operating Room

The Dishi Lingfeng system was designed to address exactly these constraints. Its master-slave teleoperation platform filters out hand tremors in real time. Motion scaling converts the surgeon's broad hand movements into micron-level precision at the instrument tips. Micro-wristed tools can rotate and articulate in ways that exceed human joint mechanics, holding steady in the confined surgical field.

During the September 2 procedure, Professor Zheng operated through the console while the robotic system executed each suture with mechanical consistency. After the anastomosis was complete, the team injected indocyanine green dye and used fluorescence imaging to confirm what the robot's precision had achieved: the lymphatic-venous connection was fully patent, with fluid flowing freely through the newly created channel.

The patient recovered smoothly.

From First Case to Clinical Evidence

The surgery was more than a technical demonstration. It was the first patient enrollment in a multi-center registered clinical trial evaluating the safety and effectiveness of the Dishi Lingfeng microsurgical system for both free flap transplantation and lymphaticovenular anastomosis. Zhejiang Provincial People's Hospital serves as the lead site, with additional centers across China expected to participate.

For Dessight Biomedical, the milestone validates years of development work and positions the company at the forefront of China's push into surgical robotics. The registered trial will generate the clinical evidence needed for regulatory approval — real patient data, rigorously collected, that can answer whether robotic-assisted LVA delivers on its theoretical promise: greater precision, shorter learning curves, more consistent outcomes.

"As the lead institution, we will work with multiple centers across the country to complete patient enrollment with high quality," Professor Zheng said. "We will use real, evidence-based Chinese data to advance domestically developed microsurgical robots toward clinical application."

The trial now moves into its enrollment and follow-up phase. If the data bear out the early results, robotic-assisted LVA could transform treatment for lymphedema patients — offering not just symptom management, but functional restoration, performed with a precision that human hands alone cannot sustain.

Source: Dessight Biomedical